Halozyme Therapeutics (HALO) Assets Average (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Assets Average data on file, last reported at $2.6 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $2.6 billion, up 22.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 22.02% YoY), and the FY2025 annual result was $2.3 billion, up 20.86% from the prior year.
• Assets Average climbed to $2.6 billion in Q1 2026 per HALO's latest filing, from $2.4 billion in the prior quarter.
• Over five years, Assets Average peaked at $2.6 billion in Q1 2026 and troughed at $1.1 billion in Q1 2022.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2023: Assets Average surged 64.88% in 2022, then dropped 2.16% in 2023.
• A 5-year view of Assets Average shows it stood at $1.9 billion in 2022, then decreased by 2.16% to $1.8 billion in 2023, then advanced by 15.32% to $2.1 billion in 2024, then advanced by 13.51% to $2.4 billion in 2025, then advanced by 9.51% to $2.6 billion in 2026.
• Business Quant data shows HALO's Assets Average at $2.6 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.